A wide metanalysis reported that ACEi/ARBs did not worsen COVID-19 severity in treated patients, suggesting on the contrary possible protective effects of RAS-inhibitors in COVID-19 management thanks to a potential pharmacogenomics rebalancing of ACE1/ACE2 equilibrium directly affected by SARS-CoV-2 entry (Gemmati et al., 2020; Gemmati and Tisato, 2020; Guo et al., 2020). The gene discussed is ACE2; the disease is COVID-19.